Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Cash & Equivalents (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Cash & Equivalents for 6 consecutive years, with $152.4 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 14.71% to $152.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $152.4 million through Dec 2025, down 14.71% year-over-year, with the annual reading at $152.4 million for FY2025, 14.71% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $152.4 million at TScan Therapeutics, down from $169.5 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $242.2 million in Q2 2024, with the low at $95.6 million in Q1 2023.
  • Average Cash & Equivalents over 5 years is $151.4 million, with a median of $146.6 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents skyrocketed 363.93% in 2021, then tumbled 32.11% in 2023.
  • Over 5 years, Cash & Equivalents stood at $161.4 million in 2021, then dropped by 25.64% to $120.0 million in 2022, then increased by 11.11% to $133.4 million in 2023, then surged by 33.99% to $178.7 million in 2024, then fell by 14.71% to $152.4 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $152.4 million, $169.5 million, and $169.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.